Yissum - Research Development Company of the Hebrew University

Oxidized Cellulose Used to Prevent Allergic Reaction in Asthma, Seasonal Allergies, and Atopic Dermatitis

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

A new composition of matter comprising microparticles with both oxidized cellulose and glucans. The composition includes pharmaceutically acceptable carrier and as an active ingredient oxidized cellulose. Preferable the oxidized cellulose should be formed as microparticles and the combimation can be used for the treatment of asthma and allergy.
keywords: formulation, allergy
Project ID : 7-2006-398

Description of the technology

Categories

Air born allergies including Asthma, hay fever, atopic dermatitis.

Development Stage

In vivo and in vitro studies have been completed as well as development of the medical device

Patent Status

Granted Patents

Highlights

  • Prevention of IgE-mediated allergic reaction by blocking and clearing pollen allergens with oxidized cellulose via its polysaccharide binding domain.
  • Mode of administration: inhalation, intranasal, ocular, topical and mucosal.
  • Oxidized cellulose has a long safety track record as an invasive medical device.
  • A commercial source of GMP manufactured oxidized cellulose has been selected.
  • Easy 510(k) regulatory pathway for certain indications.

Our Innovation

  • Oxidized cellulose, effectively prevents allergies, asthma and hay fever.
  • This is a biodegradable and biocompatible product that has exhibited a high efficiency for binding a broad-spectrum of allergens (pollen, mites, egg and cat dander).
  • The low solubility level enables it to be cleared by the mucocilliary system from the airways to the gastro-intestinal track. In addition, the oxidised cellulose, bind the allergens and prevents epithelium barrier penetration thus prevents allergic reaction..
  • The half life of oxidized cellulose is 14 days in the lungs and 55 days in the body.
  • Mouse and Rat models (in vivo and in vitro) have established oxidized cellulose powder inhalation as an effective treatment in the reduction of allergic inflammation in the lungs.
  • In-vitro assays have been developed to demonstrate mode of action and

The opportunity

  • 5 to 15% of the population in industrialized world have asthma. The prevalence and morbidity of asthmas has been on the rise, despite standard (steroids) and new treatments.
  • Asthma is the third leading cause of hospitalization among persons under the age of 18.
  • Allergy related symptoms such as atopic dermatitis and hay fever affect huge populations.

Development Milestones

  • The project is presently seeking to raise additional funding for clinical development

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Oded Shoseyov
HUJI, Faculty of Agricultural, Food and Environmental Quality Sciences
Plant Sciences and Genetics

David Shoseyov
HUJI, School of Medicine - IMRIC

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology
  • dermatology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.